Drugs, Diseases and the Managed Care Impact

(EDU-D6) Oncology Biosimilars: Formulary Trends, Evidence, and Strategies from the Payer and Patient Advocate Perspective

Thursday, October 13, 2022

4:30 PM – 5:45 PM ET

Location: Potomac B

ACPE UAN:0233-0000-22-045-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Timothy Mok, PharmD, BCPS, BCOP

Hematology Oncology Pharmacy Research Analyst
Kaiser Permanente
Livermore, CA
Therese Mulvey, MD

Director Quality Safety and Value
MGH
Boston, MA

Moderator(s)

KG

Kenneth Garcia, PharmD

Clinical Advisor
CVS Health
Portland, Oregon

This activity is supported by an independent medical education grant from Coherus BioSciences, Inc.

In 2021, there was an estimated 1.9 million new cases of cancer diagnosed, and about 608,570 people who died from the disease. Patient expenditures, both in time and out-of-pocket costs, exceed $20 billion annually adding to the complexity of cancer treatment. Biosimilars are considered an opportunity to reduce the financial burden of cancer treatment and contribute to improved outcomes for patients.

This session will include an overview of the new and emerging oncology biosimilar products, with a focus on utilization trends, substitution considerations, and the managed care and patient advocacy perspectives. This will allow managed care professionals to align current and future formulary decisions with the evolving treatment landscape and patients’ needs.

Learning Objectives:

At the completion of this activity, participants should be able to:

Differentiate new and emerging oncology biosimilars based on clinical data, manufacturer launch, and indications for use.
Evaluate oncology biosimilar outcomes data from clinical trials and real-world evidence to guide optimal substitution in an expanding market.
Discuss strategies and ongoing gaps in utilization of oncology biosimilars from the patient advocate perspective.